US 2020/0393459 A1Published application

Ceacam1 based point-of-care cancer diagnostic

OwnerGal Markelinventor

Life of this patent

Estimating the term…

Abstract

The present technology regards the utilization of CAECAM1 as a biomarker for cancer. In particular the present invention regards the detection and measurement of soluble CAECAM1 levels for the detection and diagnosis of melanoma.

Claims5

Dependent claims

A device for the point-of-care detection of soluble CAECAM1 in a biological sample, the device comprising an immunochromatographic strip for the point-of-care detection of CEACAM1 in a biological sample.

Dependencies are inferred from the claim text.

Facts

Application: 16/883,298Filed 26 May 2020
Priority: 5 Nov 2007
Published: 17 Dec 2020
Term ends: Not estimatedThe source records don’t support an estimate.

Classification4 codes

G01N 33/54388
Immunochromatographic test strips: based on lateral flow
G01N 33/57565
For cancer: involving carcinoembryonic antigen [CEA]
G01N 2333/70596
Assays involving receptors, cell surface antigens or cell surface determinants: molecules with a "CD"-designation not provided for elsewhere in…
G01N
Investigating or analysing materials by determining their chemical or physical properties

Family

Application60/985,484Us provisional application · filed 5 Nov 2007
Application12/265,469Continuation · filed 5 Nov 2008
Application16/883,298Continuation
US 10,663,464 B2Related patent
US 12,130,287 B2Related patent
US 2009/0181403 A1Published application
US 2020/0393459 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

patentgrepSearch patents

Back to results